We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+12.02%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$142M
AUM Growth
+$4.53M
Cap. Flow
+$996K
Cap. Flow %
0.7%
Top 10 Hldgs %
70.5%
Holding
62
New
2
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$1.08M
2
PRTA icon
Prothena Corp
PRTA
+$518K
3
VTYX
Ventyx Biosciences
VTYX
+$266K
4
SRPT icon
Sarepta Therapeutics
SRPT
+$252K
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$131K

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$602K
2
CGEM icon
Cullinan Oncology
CGEM
+$269K
3
FHTX icon
Foghorn Therapeutics
FHTX
+$257K
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$225K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40K

Sector Composition

Rank Sector Weight
1 Healthcare 93.28%
2 Energy 4.01%
3 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$51.7M 36.43%
727,785
– –
ELUT icon
2
Elutia
ELUT
$42M
$10.2M 7.19%
1,418,123
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$9.05M 6.37%
85,240
– –
PRTA icon
4
Prothena Corp
PRTA
$453M
$7.21M 5.08%
118,945
+16,397
+16% +$518K
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$4.38M 3.09%
61,306
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.38B
$4.08M 2.87%
249,400
– –
OVV icon
7
Ovintiv
OVV
$16.2B
$3.87M 2.73%
84,200
– –
AXDX
8
DELISTED
Accelerate Diagnostics
AXDX
$3.42M 2.41%
225,239
– –
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$3.14M 2.21%
15,000
– –
BDSX icon
10
Biodesix
BDSX
$209M
$3.01M 2.12%
118,504
+27,933
+31% +$1.08M
CLR
11
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$2.58M 1.82%
38,600
– –
FHTX icon
12
Foghorn Therapeutics
FHTX
$305M
$2.27M 1.6%
264,843
-20,000
-7% -$257K
ALBO
13
DELISTED
Albireo Pharma Inc
ALBO
$2.27M 1.59%
117,000
+4,000
+4% +$82.7K
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.23M 1.57%
14,730
-270
-2% -$40K
HROW icon
15
Harrow
HROW
$1.74B
$2.17M 1.53%
180,000
– –
MASI
16
DELISTED
Masimo
MASI
$2.16M 1.52%
15,280
– –
PHR icon
17
Phreesia
PHR
$662M
$2.11M 1.48%
82,700
– –
GOSS icon
18
Gossamer Bio
GOSS
$83.2M
$1.91M 1.34%
159,088
– –
VTYX
19
DELISTED
Ventyx Biosciences
VTYX
$1.57M 1.11%
45,000
+12,000
+36% +$266K
KPTI icon
20
Karyopharm Therapeutics
KPTI
$216M
$1.47M 1.04%
17,955
– –
CORT icon
21
Corcept Therapeutics
CORT
$9.72B
$1.28M 0.9%
50,000
– –
INBX
22
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.26M 0.89%
70,448
– –
CYTK icon
23
Cytokinetics
CYTK
$10.9B
$1.21M 0.85%
25,000
– –
AVEO
24
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.15M 0.81%
140,000
– –
ALKS icon
25
Alkermes
ALKS
$8.79B
$1.12M 0.79%
50,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Birchview Capital held 62 positions worth $142M, up 3.3% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Birchview Capital's Q3 2022 filing shows 2 new, 5 increased, 4 reduced and 2 closed positions. Its largest new stake was Sarepta Therapeutics: 2,500 shares worth $276K. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $602K.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2022 buy was Sarepta Therapeutics: 2,500 shares worth $276K.
  • Birchview Capital added most to Biodesix in Q3 2022, an estimated $1.08M increase.
  • Birchview Capital's biggest Q3 2022 reduction was Cullinan Oncology, cutting an estimated $269K.
  • Birchview Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $602K.
  • Birchview Capital's ten largest holdings make up 71% of its $142M portfolio in Q3 2022.
  • Birchview Capital opened 2 new positions and closed 2 in Q3 2022.
  • Birchview Capital's portfolio value rose 3.3% quarter-over-quarter to $142M.

Based on Birchview Capital's 13F filing for Q3 2022, filed 7 Nov 2022.